This evolutionary theory could explain the molecular mechanisms that emerged during tumor evolution in the patient in our case after mTOR inhibitor treatment, and restoration of these alterations would re-sensitize cells in HER2-low MBC to MTAs. The gene discussed is MTOR; the disease is neoplasm.